home





























 

















 





















hrsa

participating institutions:
Johns Hopkins University AIDS Service, New York State DOH AIDS Institute, The CORE Center, Cook County Hospital



OPPORTUNISTIC INFECTION PREVENTION

last updated: August 20, 1999


COMPLETE GUIDELINES:


html pdf selected tables panel members


RELATED INFORMATION:


faqsnewslinks


References

  1. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR 1995;44(No. RR-8).
  2. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease specific recommendations. Clin Infect Dis 1995;21(suppl 1):S32-S43.
  3. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. Ann Intern Med 1996;124:348-68.
  4. USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1997;46(No. RR-12).
  5. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. Clin Infect Dis 1995;21(suppl 1):S1-S11.
  6. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med 1997; 127:922-46.
  7. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Am Fam Physician 1997; 56:823-34, 1131-46, 1387-92.
  8. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Pediatrics 1998; 102:1064-85.
  9. Kaplan JE, Masur H, Jaffe HW, Holmes KK. Preventing opportunistic infections in persons infected with HIV: 1997 guidelines (editorial). JAMA 278:337-338, 1997.
  10. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1998; 128:1057-1100.
  11. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis 1994; 18:421.
  12. El-Sadr W, Oleske JM, Agins BD, et al. Evaluation and management of early HIV infection. Clinical practice guideline no. 7. Rockville, MD: US Department of Health and Human Services, Public Health Service, 1994; AHCPR publication no. 94- 0572.
  13. Phair J, Munoz A, Detels R, et al. and the Multicenter AIDS Cohort Study Group. The risk of Pneumocystis carinii pneumonia among men infected with HIV-1. N Engl J Med 1990; 322:1607.
  14. Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus Ð infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998; 178:1126-1132.
  15. Masur H. (Chairman): Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with HIV. MMWR 1989; 38(S5):1-9.
  16. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:693.
  17. Schneider MME, Hoepelman AIM, Eertlnck Schattenkerk JKM, et al., and the Dutch AIDS Treatment Group. A controlled trial of aerosolized pentamidine or trimethopirm-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonias in patients with human immunodeficiency virus. N Engl J Med 1992; 327:1836.
  18. El-Sadr W, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in HIV infected individuals. Clin Infect Dis 1999; in press.
  19. Schneider MME, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. J Infect Dis 1995; 171:1632.
  20. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prohylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992; 117:106.
  21. Hardy WD, Feinberg J, Finkelstein DM, et al., for the AIDS Clinical Trials Group. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials group 021. N Engl J Med 1992; 327:1842.
  22. Leoung G, Standford J, Giordano M, et al. A randomized, double-blind trial of TMP/SMX dose escalation vs. direct challenge in HIV+ persons at risk for PCP and with prior treatment-limiting rash or fever. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28- October 1, 1997, Abstract No. LB10.
  23. Para MF, Dohn M, Frame P, et al., for the ACTG 268 Study Team: ACTG 268 Trial Ð gradual initiation of trimethoprim/sulfamethoxazole (T/S) as primary prophylaxis for Pneumocystis carinii pneumonia (PCP). In: Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC. Alexandria, VA, Westover Management Group, 1997, Abstract No. 2.
  24. Podzamczer D, Salazar A, Jiminez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995; 122:755.
  25. Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1995; 20:531.
  26. El Sadr W, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med 1998; 339:1889- 95.
  27. Caldwell P, Murphy R, Chan C. Atovaquone suspension for prophylaxis of Pneumocystis carinii pneumonia; effects of baseline prophylaxis on safety and efficacy. In: Conference Records, 12th World AIDS Conference, Geneva, June 28- July 3, 1998, Abstract No. 22718.
  28. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med 1999; 340:1301-6.
  29. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet 1999; 353:1293-8.
  30. Schneider MME, Borleffs JCC, Stokl RP et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis in HIV-1 infected patients treated with highly active antiretroviral therapy. Lancet 1999; 353:201-3.
  31. Dworkin M, Hanson D, Jones J, Kaplan J, and the Adult/Adolescent Spectrum of HIV Disease Project (ASD). The risk for Pneumocystis carinii pneumonia (PCP) and disseminated nontuberculous mycobacteriosis (dMb) after an antiretroviral therapy (ART) associated increase in the CD4+ T-lymphocyte count. In: Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL. January 31 -February 4, 1999. Abstract No. 692.
  32. Lopez JC, Pena JM, Miro JM, Podzamczer D, and the GESIDA 04/98 Study Group. Discontinuation of PCP prophylaxis (PRO) is safe in HIV-infected patients (PTS) with immunological recovery with HAART. Preliminary results of an open, randomized and multicenter clinical trial (GESIDA 04/98). In: Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL January 31 -February 4, 1999; Abstract No. LB7.
  33. CDC. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995; 44(No. RR-4).
  34. Dannemann B, McCutchan JA, Israelski K, et al. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 1992; 116:33.
  35. Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22:268.
  36. Holmberg SD, Moorman AC, Von Bargen JC, et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV diseases. JAMA 1998; 279:384.
  37. CDC Conference on HIV-Related Tuberculosis. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998; 47 (RR-20).
  38. Masur H, and the Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993; 329:898.
  39. Benson CA, Cohn DL, Williams P, and the ACTG 196/CPCRA 009 Study Team. A phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin (CLA) vs. rifabutin (RBT) vs. CLA + RBT for prevention of Mycobacterium avium complex (MAC) disease in HIV+ patients with CD4 counts < 100 cells/uL. In: Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC. Alexandria, VA, Foundation for Retrovirology and Human Health, 1996, Abstract No. 205.
  40. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335:384-91.
  41. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996; 335:392.
  42. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease in patients with AIDS. Ann Intern Med 1994; 121:905.
  43. Cohn DL, Fisher E, Peng GT, et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high dose clarithromycin. Clin Infect Dis (in press).
  44. Shafran SD, Singer J, Zarowney DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl. J Med 1996; 335:377,
  45. Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:857-862.
  46. Ward JW, Hanson DL, Jones J, Kaplan J. Pneumococcal vaccination and the incidence of pneumonia among HIV-infected persons. In: Program and abstracts of the 34th Annual Meeting of the Infectious Diseases Society of America. Alexandria, Virginia: Infectious Diseases Society of America, 1996, Abstract No. 245.
  47. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46(No. RR-8):1-24.
  48. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332:700.
  49. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women withHIV infection. Ann Intern Med 1997; 126:689.
  50. Havlir DV, Dube MP, McCutchan A, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998; 27:1369-75.
  51. Aleck KA, Bartley DL. Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am J Med Genet 1997; 72:253-6.
  52. Pursley TJ, Blomquist IK, Abraham J, Andersen HF, Bartley JA. Fluconazole-induced congenital anomalies in three infants. Clin Infect Dis 1996; 22:336-40.
  53. Janssen Pharmaceutical Company. Product information: Sporanox oral solution. Physicians Desk Reference, Medical Economics Company, 1999; 1441.
  54. Wheat J, Hafner R, Wulfson M, et al., and the NIASID Clinical Trails & Mycoses Study Group Collaborators: Prevention of relapse histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993; 118:610.
  55. McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis against fungal infections in patients with advanced human immunodeficiency virus infection: randomized placebo-controlled double-blind study. Clin Infect Dis 1999; 28:in press.
  56. Galgiani JN, Cloud GA, Catanzaro A, et al. Fluconazole (FLU) vs. itraconazole (ITRA) for coccidioidomycosis. Randomized, multicenter, double-blinded trial in nonmeningeal progressive infections. In: Abstracts from 36th Annual Meeting of the Infectious Diseases Society of America. Alexandria, Virginia: Infectious Diseases Society of America, 1998, Abstract No. 100.
  57. Spector SA, McKinley GF, Lalezari FP, et al. Oral ganciclovir for the prevention of cytomegalovirus retinitis in persons with AIDS. N Engl J Med 1996; 334:1491.
  58. Brosgart CL, Torres RA, Thompson MA, et al. A randomized, placebo controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. AIDS 1998; 12:269.
  59. Martin DF, Kupperman BD, Wolitz RA. Oral ganciclovir for cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med 1999; 340:1063-70.
  60. Drew WL, Ives D, Lalezari J, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995; 333:615.
  61. Studies of Ocular Complication of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. Ann Intern Med 1997; 126:264.
  62. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115:665.
  63. Studies of the Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trials Group. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcomes in patients with AIDS and CMV retinitis treated with either foscarnet or ganciclovir. J Infect Dis 1997; 176:50.
  64. Whitcup SM, Fortin E, Lindblad AS, et al. Successful discontinuation of specific anti-cytomegalovirus therapy in persons with HIV infection and cytomegalovirus retinitis: results of a longitudinal intervention trial. Pending.
  65. Vrabec TR, Baldassano VF, Whitcup SM. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 1998; 105:1259-64.
  66. Schacker T, Zeh J, Hu HL, et al. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998; 178:1616-22.
  67. Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons Ð a double-blind placebo-controlled trial. Ann Intern Med 1998; 128:21.
  68. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute workshop. JAMA 1994; 271:1866-9.
  69. Golde S, et al. Clinical effectiveness and cost effectiveness of screening for anal squamous and intraepithelial lesions in homosexual and bisexual HIV positive men. JAMA (in press).
  70. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47 (No. RR-19).
  71. Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996; 174:690.
  72. United States Public Health Service. HIV prevention bulletin: medical advice for persons who inject illicit drugs. May 8, 1997, Atlanta, Georgia and Rockville, Maryland.
  73. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996; 45 (No. RR-15):1-30.
  74. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999; 48 (No. RR-4):1-28.
  75. Nielsen H, Kvinesdal B, Benfield TL, Lundgren JD, Konradsen HB. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection. Scand J Infect Dis 1998; 30:597-601.
  76. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991; 40 (No. RR-13).






Copyright © 2001-2002. The National AIDS Education and Training Centers Program on behalf of its AETC National Resource Center. All rights reserved.

Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this site because no single reference or service can take the place of medical training, education, and experience. Consumers are cautioned that this site is not intended to provide medical advice about any specific medical condition they may have or treatment they may need, and they are encouraged to call or see their physician or other health care provider promptly with any health related questions they may have.